SEC Tracker
Get the app

Bambusa Therapeutics BBTX

Shanshan Xu reports executive stock options and RSUs

Shanshan Xu (Director) reported option or other derivative trades in BBTX

Form
4
Filed
Importance
Routine
  1. Executive Shanshan Xu received 379,102 stock options on Oct 29, 2026
  2. 758,204 restricted stock units (shares paid out over time) were awarded on Oct 29, 2026
  3. Stock options vest over 4 years starting Oct 29, 2026
  4. RSUs vest upon stock price target of $32 for 30 days between Apr 1, 2027 and Apr 1, 2030

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Bambusa Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float not reported.

  1. Adaptimmune Therapeutics ADAP
  2. Adverum Biotechnologies ADVM
  3. AgomAb Therapeutics AGMB
  4. Alvotech ALVO
  5. Argenx ARGX